446 completed, 101 unknown, 98 terminated, 53 recruiting. 811 Phase 2, 128 Phase 1, 86 Phase 3.
Follow Bone Diseases: new trials by email Literature Review of Bone Diseases trials Research Report on Bone Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Combination Immunotherapy Targeting Sarcomas Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-07-01 | 2026-11-02 |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Sarcoma-specific CAR-T cells - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-10-30 |
| Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) DDY391 - Moderate to Severe Psoriatic Arthritis | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 88 | 2027-02-10 | 2026-11-06 |
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH) Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), core decompression - Osteonecrosis of Femoral Head | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 30 | 2026-12-31 | 2026-04-23 |
| Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | Forward Therapeutics | 210 | 2026-12-01 | 2026-10-09 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| Melatonin in Posterior Mandible Extraction Socket Melatonin group, Placebo group - Bone Loss | Phase 2 | Not yet recruiting | Cairo University | 40 | 2026-11-15 | 2026-11-06 |
| Alveolar Ridge Preservation (ARP) Study Using Alloplastic Biomaterial and a Resorbable Synthetic Membrane. A Digital Workflow (CBCT/Scanner) Evaluates Hard and Soft Tissue Volumetric Changes at 4 Months, Validating Support for the Gingival Phenotype and Buccal Bone Plate. Alveolar Ridge Preservation using a synthetic alloplastic bone substitute and a resorbable polymer membrane, Minimally invasive flapless tooth extraction followed by unassisted spontaneous healing - Alveolar Ridge Augmentation, Bone Substitutes | Phase 1 / Phase 2 | Not yet recruiting | Universidad Católica San Antonio de Murcia | 28 | 2026-11-01 | 2026-10-16 |
| Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 110 | 2026-10-31 | 2026-09-11 |
| REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial Low-dose Colchicine at 0.5mg daily, Usual Care - Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-30 | 2026-11-04 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-19 | 2026-11-09 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS Zoledronic Acid / Zoledronate 4 MG/100 ML Intravenous Solution, NaCL 0.9% Intravenous Solution - Osteomyelitis Chronic | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-09-15 | 2026-06-25 |
| A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Bicara Therapeutics | 160 | 2026-09-01 | 2026-10-13 |
| Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women Full-Spectrum Cannabis Extract 5:1 (CBD:THC) - Chronic Pain, Fibromyalgia | Phase 2 | Not yet recruiting | Associação Pan-Americana Multidisciplinar de Endocanabinologia | 80 | 2026-09-01 | 2026-08-26 |
| Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy vilamakitug, placebo - Axial Spondyloarthritis, Ankylosing Spondylitis | Phase 2 | Not yet recruiting | XBiotech, Inc. | 150 | 2026-09-01 | 2026-05-14 |
| A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly | Phase 2 | Recruiting | Marea Therapeutics | 72 | 2026-07-23 | 2026-09-11 |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | 1 | 2026-07-21 | 2026-07-23 |
Showing 20 of 811. Sign in to see all of them.
Osteoporosis (164) · Bone Diseases, Metabolic (68) · Arthritis, Psoriatic (65) · Spondylitis, Ankylosing (57) · Bone Neoplasms (53) · Dwarfism, Pituitary (44) · Intervertebral Disc Degeneration (40) · Dwarfism (34) · Osteoporosis, Postmenopausal (34) · Acromegaly (27) · Musculoskeletal Diseases (27) · Sarcoma (26) · Achondroplasia (20) · Alveolar Bone Loss (19)
Musculoskeletal Diseases (784) · Nutritional and Metabolic Diseases (271) · Metabolic Diseases (267) · Spinal Diseases (214) · Bone Diseases, Developmental (187) · Bone Diseases, Metabolic (177) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (169) · Pathological Conditions, Signs and Symptoms (145) · Joint Diseases (144) · Endocrine System Diseases (139) · Genetic Diseases, Inborn (136) · Skin and Connective Tissue Diseases (136) · Arthritis (130) · Spondylitis (129)
Alendronate (31) · Zoledronic Acid (27) · Teriparatide (25) · Denosumab (24) · Cholecalciferol (20) · Human Growth Hormone (20) · Calcium (14) · Growth Hormone (14) · Calcium Carbonate (12) · Vitamin D (12) · Etanercept (9) · vosoritide (9) · Cyclophosphamide (8) · Parathyroid Hormone (8) · Gemcitabine (7)
Novartis Pharmaceuticals (18) · Amgen (11) · Charite University, Berlin, Germany (11) · Massachusetts General Hospital (11) · Columbia University (10) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (10) · Pfizer (9) · Alexion Pharmaceuticals, Inc. (8) · Merck Sharp & Dohme LLC (8) · AbbVie (7) · BioMarin Pharmaceutical (7) · M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Eli Lilly and Company (6)
United States (403) · Germany (87) · Spain (75) · United Kingdom (71) · Canada (69) · France (69) · Poland (64) · China (61) · Australia (60) · Italy (56) · Denmark (40) · Hungary (40) · Czechia (39) · Belgium (36) · Russia (32)
Ervin Epstein, MD (5) · Thomas J Schnitzer, MD, PhD (5) · Elizabeth Shane, MD (4) · Paul Orchard, MD (4)
PMID 40194794, PMID 41807031, PMID 26529632, PMID 31401903, PMID 32417537, PMID 32762706, PMID 38649657, PMID 12795371, PMID 24476416, PMID 25769789, PMID 25919461, PMID 27699270, PMID 30334093, PMID 31269546, PMID 32461347, PMID 32721016, PMID 35789257, PMID 35833532, PMID 35931879, PMID 36178584, PMID 36792844, PMID 39151033, PMID 39890205, PMID 40576086, PMID 42144862, PMID 10976589, PMID 12877751, PMID 14500804, PMID 14695734, PMID 14988471, PMID 15674306, PMID 15722593, PMID 15883634, PMID 16076940, PMID 16087995, PMID 16093464, PMID 16231283, PMID 16430773, PMID 16449339, PMID 16495394, PMID 16996315, PMID 17077737, PMID 17116511, PMID 17164314, PMID 17192294, PMID 17333451, PMID 17577003, PMID 17592924, PMID 17708711, PMID 17763894
2019 (11), 2016 (9), 2017 (9), 2015 (8), 2009 (6), 2014 (6), 2018 (6), 2008 (5), 2023 (4), 2025 (4), P50AT000090 (3), 2005 (2), P50AR044855 (2), R01CA109584 (2), 1UL1RR025758 (1)